Clinical trial of YPS345, a class 1 innovative drug, was approved by the State Drug Administration
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, chinaPharmaceutical(http://issued a notice that its wholly-owned
subsidiary(http://Tianfang Pharmaceutical Co., Ltdreceived a notice of acceptance of the clinicaltest(http://) of the 1 class of chemical sin sinnew drugs(http://YPS345 approved by the StatePharmaceutical(http://Supervision Authority the deadline, Tianfang Limited has invested a total of about 19.84 million yuan in research and development projects in this category of drugs the YPS345 YPS345 project is a class 1 innovative chemical developed by Tianfang Pharmaceuticals and the Institute of Biophysics of the Chinese Academy of Sciences, intended to be used in the treatment of pneumonia and pulmonary fibrosis caused by chest radiation therapy in tumor patients, and there is no of the same product (http:// in the market Tianfang Pharmaceuticals in the yPS345 non-clinical trial research stage, the effectiveness and safety results show that as a drug to prevent and treat radioactive inflammation (http:// , it has significant remission to animal models of chemotherapy-induced pulmonary fibrosis, and good safety at the same time, according to the completed mechanism of action research found that YPS345 can be inhibited by the associated inflammatory factor intracellular transport and secretion of the regulatory mechanism, so as to prevent radiation-induced lung damage
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
